Semmelweis Egyetem Onkologiai Központ
About Semmelweis Egyetem Onkologiai Központ
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
9
Bristol-Myers Squibb
1
Pfizer
1
Seagen Inc.
1
Stemline Therapeutics, Inc.
1
Clinical Trials at Semmelweis Egyetem Onkologiai Központ
During the past decade, Semmelweis Egyetem Onkologiai Központ conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 8 clinical trials were completed, i.e. on
average, 114.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
2009-10-16
2017-01-24
Completed
596
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
2010-01-26
2017-08-07
Completed
452
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
2010-07-31
2016-09-16
Completed
1,095
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
2007-08-30
2016-05-31
Completed
3,942
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
2011-11-08
2028-11-30
Active, not recruiting
4,804
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
2013-06-10
2019-12-31
Completed
780
An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)
2015-01-13
2017-12-29
Completed
300
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
2015-11-30
2017-12-13
Completed
33
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Semmelweis Egyetem Onkologiai Központ" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Bristol-Myers Squibb" with 1 trials
sponsored, "Pfizer" with 1 trials sponsored, "Seagen Inc." with 1 trials sponsored and "Stemline Therapeutics, Inc."
with 1 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Semmelweis Egyetem Onkologiai Központ"
#1 collaborator was "Genentech, Inc." with 2 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Foundation Medicine, Inc." with 1 trials as a collaborator, "Genmab" with 1 trials as a collaborator and "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were
collaborators in the rest 5 trials.
Clinical Trials Conditions at Semmelweis Egyetem Onkologiai Központ
According to Clinical.Site data, the most researched conditions in "Semmelweis Egyetem Onkologiai Központ" are
"Breast Cancer" (6 trials), "Gastric Cancer" (2 trials), "Bladder Cancer" (1 trials), "Cancer of Unknown Primary Site" (1 trials) and "Cervix Cancer" (1 trials). Many other conditions were trialed in "Semmelweis Egyetem Onkologiai Központ" in a lesser frequency.
Clinical Trials Intervention Types at Semmelweis Egyetem Onkologiai Központ
Most popular intervention types in "Semmelweis Egyetem Onkologiai Központ" are "Drug" (12 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Pertuzumab" (4 trials), "5-Fluorouracil" (3 trials), "Capecitabine" (3 trials), "Trastuzumab" (3 trials) and "Atezolizumab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Semmelweis Egyetem Onkologiai Központ
The vast majority of trials in "Semmelweis Egyetem Onkologiai Központ" are
10 trials for "All" genders and 3 trials for "Female" genders.
Clinical Trials Status at Semmelweis Egyetem Onkologiai Központ
Currently, there are NaN active trials in "Semmelweis Egyetem Onkologiai Központ".
undefined are not yet recruiting,
1 are recruiting,
4 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 7 completed trials in Semmelweis Egyetem Onkologiai Központ,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Semmelweis Egyetem Onkologiai Központ, 1 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 9 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".